- Home
- CTSO vs NRXP Comparison
CTSO vs NRXP Comparison
Compare CTSO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- NRXP
- Stock Information
- Founded
- CTSO 1997
- NRXP 2015
- Country
- CTSO United States
- NRXP United States
- Employees
- CTSO N/A
- NRXP N/A
- Industry
- CTSO Medical/Dental Instruments
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- NRXP Health Care
- Exchange
- CTSO Nasdaq
- NRXP Nasdaq
- Market Cap
- CTSO 72.8M
- NRXP 58.5M
- IPO Year
- CTSO N/A
- NRXP N/A
- Fundamental
- Price
- CTSO $0.89
- NRXP $2.62
- Analyst Decision
- CTSO Buy
- NRXP Strong Buy
- Analyst Count
- CTSO 2
- NRXP 4
- Target Price
- CTSO $5.50
- NRXP $28.50
- AVG Volume (30 Days)
- CTSO 351.0K
- NRXP 344.9K
- Earning Date
- CTSO 08-07-2025
- NRXP 08-18-2025
- Dividend Yield
- CTSO N/A
- NRXP N/A
- EPS Growth
- CTSO N/A
- NRXP N/A
- EPS
- CTSO N/A
- NRXP N/A
- Revenue
- CTSO $36,107,520.00
- NRXP N/A
- Revenue This Year
- CTSO $11.15
- NRXP N/A
- Revenue Next Year
- CTSO $21.39
- NRXP $230.95
- P/E Ratio
- CTSO N/A
- NRXP N/A
- Revenue Growth
- CTSO 20.18
- NRXP N/A
- 52 Week Low
- CTSO $0.71
- NRXP $1.10
- 52 Week High
- CTSO $1.61
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- CTSO 41.50
- NRXP 45.85
- Support Level
- CTSO $1.03
- NRXP $2.30
- Resistance Level
- CTSO $1.19
- NRXP $2.95
- Average True Range (ATR)
- CTSO 0.09
- NRXP 0.22
- MACD
- CTSO 0.01
- NRXP 0.02
- Stochastic Oscillator
- CTSO 27.21
- NRXP 49.23
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.